Abstract
Due to their relatively unaggressive biological behavior, most differentiated thyroid carcinomas have a good prognosis [7, 28]. This holds true even for patients with lung metastases, particularly in cases with disseminated metastatic sites that are radioiodine-positive. Therefore, thyroid cancer is overall a rare cause of cancer-associated death. Serum thyroglobulin measurement is the most sensitive method to detect recurrence of differentiated thyroid carcinoma during follow-up [39]. Radioiodine scintigraphy can be used as a highly specific method to visualize tumor tissue. But in many cases, particularly in poorly differentiated cancer and in Hürthle cell carcinoma, radioiodine uptake is decreased or absent, owing to several mechanisms. Particularly DNA changes, encoding the Na+/I- symporter, have to be considered. Therefore, the sensitivity of radioiodine scintigraphy is decreased from about 70% to less than 50% during the clinical course [37, 46]. Although therapeutic options are often limited to some extent in patients with radioiodine-negative metastases, correct staging is very important to plan further diagnostic and therapeutic steps. But also in cases with known radioiodine-positive tumor tissue, other functional techniques are clinically useful to prove or exclude additional radioiodine-negative tumor sites, which cannot be influenced by further radioiodine treatments. In some cases, recurrence or metastases are suspected during follow-up, even if no increased thyroglobulin values are observed. The reason might be pathologic thyroglobulin recovery values or the existence of very poorly differentiated cell lines which have lost the capability of Tg synthesis. Tumor-specific functional imaging techniques are necessary to evaluate equivocal morphologic alterations in these patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adler LP, Bloom AD (1993) Positron emission tomography of thyroid masses. Thyroid 3: 195 - 200
Arturi F, Russo D, Schlumberger M, du-Villard JA, Caillou B, Vigneri P, et al. (1998) Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab 83: 2493 - 2496
Balone HR, Fing-Bennett D, Stoffer SS (1992) 99mTc-sestamibi uptake by recurrent Hürthle cell carcinoma of the thyroid. J Nucl Med 33: 1393 - 1395
Bangard M, Bender H, Grünwald F, et al. (1999) Myocardial uptake of technetium-99m-furifosmin (Q12) versus technetium-99m-sestamibi ( MIBI ). Nuklearmedizin 38: 189-191
Bauer W, Briner U, Doepfner W (1982) SMS-201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31: 1133 - 1140
Becker W, Schrell U, Buchfelder M, Hensen J, Wendler J, Gramatzki M, et al. (1995) Somatostatin receptor expression in the thyroid demonstrated with 111In-octreotide scintigraphy. Nuklearmedizin 34: 100 - 103
Biersack HJ, Hotze A (1991) The clinician and the thyroid. Eur J Nucl Med 18: 761 - 778
Brandt-Mainz K, Müller SP, Sonnenschein W, Bockisch A (1998) Technetium-99m-furifosmin in the follow-up of differentiated thyroid carcinoma. J Nucl Med 39: 1536 - 1541
Briele B, Hotze AL, Kropp J, Bockisch A, Overbeck B, Grünwald F, et al. (1991) A comparison of 201T1 and 99mTc-MIBI in the follow-up of differentiated thyroid carcinoma. Nuklearmedizin 30: 115 - 124
Briele B, Willkomm P, Grünwald F, Ruhlmann J, Biersack HJ (1999) Imaging of secondary pulmonary changes in central bronchial carcinomas by F-18-FDG-PET. Nuklearmedizin 38• 323 - 327
Dadparvar S, Chevres A, Tulchinsky M, Krishna-Badrinath L, Khan AS, Slizofski WJ (1995) Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation. Eur J Nucl Med 22: 1330 - 1338.
Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H (1997) Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 24: 1342 - 1348
Farahati J, Reiners C, Stuschke M, Müller SP, Stüben G, Sauerwein W, et al. (1996) Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer 77: 172 - 180
Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, Müller-Schauenburg W (1996) Fluorine-18-FDG and iodine-131-Iodide uptake in thyroid cancer. J Nucl Med 37: 1468 - 1472
Foldes I, Levay A, Stotz G (1993) Comparative scanning of thyroid nodules with technetium-99m pertechnetate and technetium-99m methoxyisobutylisonitrile. Eur J Nucl Med 20: 330 - 333
Gallowitsch HJ, Mikosch P, Kresnik E, Unterweger 0, Gomez I, Lind P (1998) Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma. J Nucl Med 39: 870 - 875
Görges R, Kahaly G, Müller-Brand J, et al. (1999) Examination of the somatostatin receptor status in non-medullary thyroid cancer. Nuklearmedizin 38: 15 - 23
Grünwald F, Schomburg A, Bender H, Klemm E, Menzel C, Bultmann T, et al. (1996) Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 23: 312 - 319
Grünwald F, Menzel C, Bender H, Palmedo H, Willkomm P, Ruhlmann J, et al. (1997) Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 7: 327 - 335
Grünwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R, et al. (1998) Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 39: 1903 - 1906
Grünwald F, Kälicke T, Feine U, et al. (1999) Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 26: 1547 - 1552
Gulec SA, Serafini AN, Sridhar KS, Peker KR, Gupta A, Goodwin WJ, et al. (1998) Somatostatin receptor expression in Hürthle cell cancer of the thyroid. J Nucl Med 39: 243 - 245
Hoefnagel CA, Delprat CC, Marcuse HR, deVijlder JJ (1986) Role of thallium-201 total-body scintigraphy in follow-up of thyroid carcinoma. J Nucl Med 27: 1854 - 1857
Joensuu H, Ahonen A, Klemi PJ (1988) 18F-fluorodeoxyglucose imaging in preoperative diagnosis of thyroid malignancy. Eur J Nucl Med 13: 502 - 506
Koizumi M, Taguchi H, Goto M, Nomura T, Watari T (1993) Thallium-201 scintigraphy in the evaluation of thyroid nodules. A retrospective study of 246 cases. Ann Nucl Med 7: 147 - 152
Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N (1994) Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med 35: 104 - 112
Lamberts SW, Koper JW, Reubi JC (1987) Potential role of somatostatin analogues in the treatment of cancer. Eur J Clin Invest 17: 281 - 287
Lerch H, Schober O, Kuwert T, Saur HB (1997) Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol 15: 2067 - 2075
Lind P (1999) Multi-tracer imaging of thyroid nodules: is there a role in the preoperative assessment of nodular goiter? Eur J Nucl Med 26: 795 - 797
Matthaei S, Trost B, Hamann A, Kausch C, Benecke H, Greten H, et al. (1995) Effect of in vivo thyroid hormone status on insulin signalling and GLUT1 and GLUT4 glucose transport systems in rat adipocytes. J Endocrinol 144: 347 - 357
Mezosi E, Bajnok L, Gyory F, Varga J, Sztojka I, Szabo J, Galuska L, Leovey A, Kakuk G, Nagy E (1999) The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the differential diagnosis of cold thyroid nodules. Eur J Nucl Med 26: 798 - 803
Mueckler M (1994) Facilitative glucose transporters. Eur J Biochem 219: 713 - 725
Nemec J, Nyvltova O, Blazek T, Vlcek P, Racek P, Novak Z, et al. (1996) Positive thyroid cancer scintigraphy using technetium-99m methoxyisobutylisonitrile. Eur J Nucl Med 1996; 23: 69 - 71
Ohnishi T, Noguchi S, Murakami N, Jinnouchi S, Hoshi H, Futami S et al. (1993) Detection of recurrent thyroid cancer: MR versus thallium-201 scintigraphy. AJNR Am J Neuroradiol 14: 1051 - 1057
Piwinica-Worms D, Kronauge JF, Chiu ML (1990) Uptake and retention of hexakis (2methoxyisobutyl isonitrile) technetium ( I) in cultured chick myocardial cells, mitochondrial and plasma membrane potential dependence. Circulation 82: 1826-1838
Raue F (1997) Chemotherapie bei Schilddrüsenkarzinomen: Indikation and Ergebnisse. Onkologe 3: 55 - 58
Reiners C, Reimann J, Schaffer R, Baum K, Becker W, Eilles C, et al. (1984) Metastatic differentiated thyroid cancer. Diagnostic accuracy of thyroglobulin-RIA in comparison with í131-whole-body scintigraphy. RÖFO Fortschr Geb Röntgenstr Nuklearmed 141: 306 - 313
Saito T, Endo T, Kawaguchi A, Ikeda M, Katoh R, Kawaoi A, et al. (1998) Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. J Clin Invest 101: 1296 - 1300
Schlumberger M, Fragu P, Gardet P, Lumbroso J, Vilot D, Parmentier C (1991) A new immunoradiometric assay ( IRMA) system for thyroglobulin measurement in the follow-up of thyroid cancer patients. Eur J Nucl Med 18: 153-157
Scott GC, Meier DA, Dickinson CZ (1995) Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99m-pertechnetate and iodine131-sodium iodide. J Nucl Med 36: 1843 - 1845
Sisson JC, Ackermann RJ, Meyer MA (1993) Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrin Metabol 77: 1090 - 1094
Unal S, Menda Y, Adalet I, Bortepe H, Özbey N, Alagöl F, et al. (1998) Thallium-201, technetium-99-tetrofosmin, and iodine-131 in detecting differentiated thyroid carcinoma metastases. J Nucl Med 39: 1897 - 1902
Valli N, Catargi B, Ronci N, et al. (1999) Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy. Thyroid 9: 583 - 589
VanSorge-vanBoxtel RAJ, VanEck-Smit BLF, Goslings BM (1993) Comparison of serum thyroglobulin, I-131 and TI-201 scintigraphy in the postoperative follow-up of differentiated thyroid cancer. Nucl Med Commun 14: 365 - 372
Wang W, Macapinlac H, Larson SM, et al. (1999) [18F]-2-Fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)í whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84: 2291 - 2302
Warburg 0 (1956) On the origin of cancer cells. Science 123: 309 - 314
Yoshioka T, Takahashi H, Oikawa H, Maeda S, Wakui A, Watanabe T, et al. (1994) Accumulation of 2-deoxy-2[18F]fluoro-D-glucose in human cancer heterotransplanted in nude mice: comparison between histology and glycolytic status. J Nucl Med 35: 97 - 103
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Grünwald, F. (2001). Functional Imaging of Thyroid Cancer. In: Biersack, HJ., Grünwald, F. (eds) Thyroid Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-04610-4_12
Download citation
DOI: https://doi.org/10.1007/978-3-662-04610-4_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-04612-8
Online ISBN: 978-3-662-04610-4
eBook Packages: Springer Book Archive